Skip to main
PACB
PACB logo

PACB Stock Forecast & Price Target

PACB Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 29%
Hold 57%
Sell 0%
Strong Sell 0%

Bulls say

Pacific Biosciences of California Inc recorded an improvement in gross margin year-over-year, primarily driven by a higher mix of consumables revenue, indicating a strong demand for its products. The company highlighted that the utilization of its Revio platform reached its peak since launch, suggesting robust engagement and increased sales within the Americas region. Additionally, management expressed optimism regarding sequential growth in Vega placements, which may contribute positively to the company's revenue and profitability throughout the year.

Bears say

Pacific Biosciences of California Inc. faces a negative outlook primarily due to a projected decline in gross margins, expected to fall below the 40.4% reported in the previous quarter. There are concerns regarding stagnant utilization and weaker-than-anticipated demand for new instruments, which could jeopardize the company's financial targets for 2026. Additionally, persistent demand weakness in China, noted by life science tools companies throughout FY23, indicates ongoing challenges that could impact revenue growth into 2024.

PACB has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 29% recommend Buy, 57% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pacific Biosciences of California (PACB) Forecast

Analysts have given PACB a Buy based on their latest research and market trends.

According to 7 analysts, PACB has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pacific Biosciences of California (PACB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.